P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

Introduction and Objectives: Tenofovir Alafenamide (TAF) is a preferred treatment in the most recent EASL and AASLD HBV Guidelines, especially in patients with risk factors for TDF-associated renal and bone effects. In 2 identically-designed double-blind (DB), randomized (2:1), Phase 3 studies (HBeA...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Wai Kay Seto, Ting-Tsung Chang, Abhijit Chowdhry, Chi-Yi Chen, Mustafa Kemal Celen, Xiaoli Ma, Mang Ma, Ajay Duseja, Ki Tae Yoon, Wan Cheng Chow, Leland Yee, Gregor Weber, Ms Jin Youn, John F. Flaherty, Anuj Gaggar, Bing Gao, Gregory Camus, Eric Bassetti, Jae Seok Hwang, Tetshuro Inokuma, Young- Suk Lin, Edward J. Gane
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2023-03-01
Rangatū:	Annals of Hepatology
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S1665268123000091
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!